ORIGINAL
Introduction: Glioblastoma is the most common primary malignant tumor of the central nervous system. Furthermore, this tumor has a high morbidity and mortality rate. It is therefore necessary to understand the population that is most affected by this pathology. Objective: To analyze the epidemiological profile of hospital admissions for glioblastoma in Brazil between 2012 and 2021. Methods: A retrospective cross-sectional study with a quantitative approach, with data collected from the Hospital Cancer Registry System (SisRHC) database. Results: 13,764 cases of hospitalization for glioblastoma were found, of which 7,927 were male and 5,756 were female. The approximate prevalence was 6.04 per 100,000 inhabitants. However, the geographical distribution was heterogeneous between the Brazilian Federative Units (FU). Approximately 73.9% of patients with this pathology were over 50 years old. Conclusion: Brazil has a prevalence similar to that found in other countries. Furthermore, the distribution among the UFs was mainly due to restricted access to neurology and neurosurgery services. Thus, a predominance of male cases was observed to the detriment of female cases. The incidence of glioblastomas increases after the age of 50, with a peak between 55 and 65. In addition, it was found that there is a higher prevalence among white people when compared to other ethnic groups. In terms of pathology, the frontal, parietal and temporal lobes were the most frequent primary locations. As for treatment, the most widely used approach in the country is radiotherapy in monotherapy and the most common outcome was death.
1. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-oncol. 2020;22(8):1073-113. http://dx.doi.org/10.1093/neuonc/ noaa106. PMid:32328653.
2. Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023;329(7):574-87. http:// dx.doi.org/10.1001/jama.2023.0023. PMid:36809318.
3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-oncol. 2021;23(8):1231-51. http://dx.doi.org/10.1093/neuonc/noab106. PMid:34185076.
4. Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. Neuro-oncol. 2017;19(11):1553-64. http://dx.doi.org/10.1093/neuonc/nox091. PMid:28482030.
5. Davis FG, Smith TR, Gittleman HR, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015. Neuro-oncol. 2020;22(2):301-2. http://dx.doi.org/10.1093/neuonc/noz203. PMid:31786602.
6. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315- 29. http://dx.doi.org/10.1016/S1470-2045(17)30194-8. PMid:28483413.
7. Batistella GNR, Santos AJ, Paiva Neto MA, et al. Approaching glioblastoma during COVID-19 pandemic: current recommendations and considerations in Brazil. Arq Neuropsiquiatr. 2021;79(2):167-72. http://dx.doi.org/10.1590/0004-282x-anp-2020-0434. PMid:33759984.
8. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96. http://dx.doi.org/10.1056/NEJMoa043330. PMid:15758009.
9. Lah TT, Novak M, Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin Cancer Biol. 2020;60:262-73. http://dx.doi. org/10.1016/j.semcancer.2019.10.010. PMid:31654711.
10. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1985-96. http://dx.doi.org/10.1158/1055- 9965.EPI-14-0275. PMid:25053711.
11. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Instituto Nacional de Câncer. SISRHC: Hospital Cancer Registry System. 2005. Available from: https://pesquisa.bvsalud.org/bvsms/resource/pt/mis- 34173. Accessed: 11/4/2023
12. Instituto Brasileiro de Geografia e Estatística. Available from: https:// www.ibge.gov.br/. Accessed: 11/7/2023
13. Microsoft. Microsoft Excel. Available from: https://www.microsoft. com/pt-br/microsoft-365/excel. Accessed: 11/7/2023
14. Carrano A, Juarez JJ, Incontri D, Ibarra A, Guerrero Cazares H. Sex-specific differences in glioblastoma. Cells. 2021;10(7):1783. http:// dx.doi.org/10.3390/cells10071783. PMid:34359952.
15. Barreto MC, Kosminsky D, Esperança C. Hexagonal hierarchical cartogram: towards a thematic map of Brazil. InfoDesign. 2018;15(1):45- 62. http://dx.doi.org/10.51358/id.v15i1.563.
16. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro-oncol. 2023;25(Supplement_4):iv1-99. http://dx.doi.org/10.1093/neuonc/noad149. PMid:37793125.
17. Luo C, Song K, Wu S, et al. The prognosis of glioblastoma: a large, multifactorial study. Br J Neurosurg. 2021;35(5):555-61. http://dx.doi. org/10.1080/02688697.2021.1907306. PMid:34236262.
1MS, Medicine Student, Centro Universitário de Brasília, Liga Acadêmica de Neurociências do UniCEUB – LIANU, Brasília, DF, Brazil.
2MS, Medicine Student, Centro Universitário do Planalto Central Apparecido dos Santos, Brasília, DF, Brazil.
3MD, Graduated at Escola Superior de Ciências da Saúde, Brasília, DF, Brazil.
4MS, Medicine Student, Instituto Tocantinense Presidente Antônio Carlos – ITPAC, Porto Nacional, TO, Brazil.
5MD, Graduated at Centro Universitário de Brasília, Brasília, DF, Brazil.
6PhD in Molecular Pathology, Centro Universitário de Brasília, Brasília, DF, Brazil.
Received Nov 12, 2023
Accepted Jan 14, 2024
